Precipio Inc (PRPO)

$6.51 +0.36 (5.85%)
Market Cap 9.12M
Revenue (ttm) 15.20M
Net Income (ttm) -5.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -38.49%
Debt to Equity Ratio 0.04
Volume 10,800
Avg Vol 6,320
Day's Range N/A - N/A
Shares Out 1.48M
Stochastic %K 100%
Beta 1.41
Analysts Strong Buy
Price Target $40.00

Latest News on PRPO

Precipio grants senior management performance-based awards instead of traditional time-vested ESOPs

Jan 16, 2025, 5:00 PM EST - 1 day ago

Precipio grants senior management performance-based awards instead of traditional time-vested ESOPs

Precipio, Inc. (PRPO) Q3 2024 Earnings Call Transcript

Nov 18, 2024, 6:16 PM EST - 2 months ago

Precipio, Inc. (PRPO) Q3 2024 Earnings Call Transcript

Precipio Announces Q3-2024 Shareholder Update Call

Nov 6, 2024, 5:00 PM EST - 2 months ago

Precipio Announces Q3-2024 Shareholder Update Call

Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping

Oct 8, 2024, 10:00 AM EDT - 3 months ago

Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping

Precipio Announces Employee Stock Option Plan Repricing

Sep 6, 2024, 4:00 PM EDT - 4 months ago

Precipio Announces Employee Stock Option Plan Repricing

Precipio, Inc. (PRPO) Q2 2024 Earnings Call Transcript

Aug 19, 2024, 5:55 PM EDT - 5 months ago

Precipio, Inc. (PRPO) Q2 2024 Earnings Call Transcript

Precipio Announces Q2-2024 Shareholder Update Call

Aug 15, 2024, 5:00 PM EDT - 5 months ago

Precipio Announces Q2-2024 Shareholder Update Call

Precipio Reports $0.3M cash generated by operations (unaudited) in Q2-2024, as the company advances towards breakeven

Jul 25, 2024, 9:00 AM EDT - 6 months ago

Precipio Reports $0.3M cash generated by operations (unaudited) in Q2-2024, as the company advances towards breakeven

Precipio Reports $4.4M for Q2-2024 (unaudited) Revenues, a leap of 30% from Q1-2024

Jul 17, 2024, 9:00 AM EDT - 6 months ago

Precipio Reports $4.4M for Q2-2024 (unaudited) Revenues, a leap of 30% from Q1-2024

Precipio Inc. Announces Adjournment of Annual Meeting of Stockholders

Jun 13, 2024, 4:00 PM EDT - 7 months ago

Precipio Inc. Announces Adjournment of Annual Meeting of Stockholders

Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting

Jun 12, 2024, 4:00 PM EDT - 7 months ago

Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting

Precipio Secures a short-term $500K Credit Facility

May 6, 2024, 5:00 PM EDT - 9 months ago

Precipio Secures a short-term $500K Credit Facility

Precipio Announces Year end 2023 Shareholder Update Call

Mar 25, 2024, 5:00 PM EDT - 10 months ago

Precipio Announces Year end 2023 Shareholder Update Call

Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY

Feb 13, 2024, 10:00 AM EST - 1 year ago

Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY

Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer

Feb 6, 2024, 10:00 AM EST - 1 year ago

Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer

Precipio's Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter

Jan 23, 2024, 10:00 AM EST - 1 year ago

Precipio's Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter

Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan

Jan 17, 2024, 10:30 AM EST - 1 year ago

Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan

Precipio Announces Christina Valauri joins the Board of Directors

Jan 2, 2024, 9:00 AM EST - 1 year ago

Precipio Announces Christina Valauri joins the Board of Directors

Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024

Dec 14, 2023, 4:30 PM EST - 1 year ago

Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024

Precipio, Inc. (PRPO) Q3 2023 Earnings Call Transcript

Nov 20, 2023, 6:38 PM EST - 1 year ago

Precipio, Inc. (PRPO) Q3 2023 Earnings Call Transcript

Precipio Announces Q3-2023 Shareholder Update Call

Nov 16, 2023, 5:00 PM EST - 1 year ago

Precipio Announces Q3-2023 Shareholder Update Call

Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022

Oct 18, 2023, 9:00 AM EDT - 1 year ago

Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022

Precipio's Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023

Oct 3, 2023, 10:00 AM EDT - 1 year ago

Precipio's Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023

Precipio Continues to Sign New HemeScreen™ Customers

Sep 28, 2023, 9:00 AM EDT - 1 year ago

Precipio Continues to Sign New HemeScreen™ Customers

Precipio Reduces Product Revenue Result Needed for Cash Flow Breakeven

Sep 25, 2023, 11:00 AM EDT - 1 year ago

Precipio Reduces Product Revenue Result Needed for Cash Flow Breakeven

Precipio Takes Final Step Towards Regaining Nasdaq Compliance

Sep 21, 2023, 9:00 AM EDT - 1 year ago

Precipio Takes Final Step Towards Regaining Nasdaq Compliance

Precipio's Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of Plan

Sep 13, 2023, 9:30 AM EDT - 1 year ago

Precipio's Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of Plan

Precipio, Inc. (PRPO) Q2 2023 Earnings Call Transcript

Aug 17, 2023, 6:32 PM EDT - 1 year ago

Precipio, Inc. (PRPO) Q2 2023 Earnings Call Transcript

Precipio Announces Q2-2023 Shareholder Update Call

Aug 10, 2023, 5:00 PM EDT - 1 year ago

Precipio Announces Q2-2023 Shareholder Update Call

Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel

Aug 8, 2023, 9:00 AM EDT - 1 year ago

Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel

Precipio's Operational Efficiency Measures Continue To Reduce Cash Burn And Move The Company Towards Breakeven

Aug 3, 2023, 9:00 AM EDT - 1 year ago

Precipio's Operational Efficiency Measures Continue To Reduce Cash Burn And Move The Company Towards Breakeven

Precipio Unaudited Q2-2023 Revenues Show combined increase of 25% over Q1-2023

Aug 1, 2023, 9:00 AM EDT - 1 year ago

Precipio Unaudited Q2-2023 Revenues Show combined increase of 25% over Q1-2023

Precipio's Omnia™ Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy

Jun 14, 2023, 9:49 AM EDT - 1 year ago

Precipio's Omnia™ Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy

Precipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen® Technology

Jun 13, 2023, 9:00 AM EDT - 1 year ago

Precipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen® Technology

Precipio, Inc. Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement

Jun 8, 2023, 8:30 AM EDT - 1 year ago

Precipio, Inc. Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement

Projected cash burn reduced by $1.5 million annually from Three Operational Efficiency Projects

Jun 7, 2023, 9:30 AM EDT - 1 year ago

Projected cash burn reduced by $1.5 million annually from Three Operational Efficiency Projects

Precipio's Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology

May 22, 2023, 11:00 AM EDT - 1 year ago

Precipio's Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology

Precipio, Inc. (PRPO) Q1 2023 Earnings Call Transcript

May 18, 2023, 12:34 PM EDT - 1 year ago

Precipio, Inc. (PRPO) Q1 2023 Earnings Call Transcript

Precipio Shares Growth Catalysts For HemeScreen

May 17, 2023, 4:00 PM EDT - 1 year ago

Precipio Shares Growth Catalysts For HemeScreen

Precipio Announces Q1-2023 Shareholder Update Call

May 15, 2023, 4:00 PM EDT - 1 year ago

Precipio Announces Q1-2023 Shareholder Update Call

Precipio Adds Substantial Pathology Customer to its Diagnostic Services Division

May 4, 2023, 1:00 PM EDT - 1 year ago

Precipio Adds Substantial Pathology Customer to its Diagnostic Services Division

Precipio Signs Another HemeScreen™ Customer

May 4, 2023, 10:00 AM EDT - 1 year ago

Precipio Signs Another HemeScreen™ Customer

Precipio Granted 180-day Extension From NASDAQ To Regain Compliance

Apr 27, 2023, 5:00 PM EDT - 1 year ago

Precipio Granted 180-day Extension From NASDAQ To Regain Compliance

Precipio Unaudited Q1-2023 Product Revenues Exceed The Two Prior Quarters (Q3+Q4 of 2022) Combined

Apr 19, 2023, 11:00 AM EDT - 1 year ago

Precipio Unaudited Q1-2023 Product Revenues Exceed The Two Prior Quarters (Q3+Q4 of 2022) Combined

Precipio, Inc. (PRPO) Q4 2022 Earnings Call Transcript

Apr 3, 2023, 7:10 PM EDT - 1 year ago

Precipio, Inc. (PRPO) Q4 2022 Earnings Call Transcript

Precipio Announces 2022 Fourth Quarter and Year-End Shareholder Update Call

Mar 28, 2023, 5:00 PM EDT - 1 year ago

Precipio Announces 2022 Fourth Quarter and Year-End Shareholder Update Call

Precipio Ships First IV-Cell® Order to Major US Healthcare System

Mar 21, 2023, 10:30 AM EDT - 1 year ago

Precipio Ships First IV-Cell® Order to Major US Healthcare System

CORRECTION -- Precipio continues to sign up and onboard HemeScreen™ customers

Mar 7, 2023, 12:49 PM EST - 2 years ago

CORRECTION -- Precipio continues to sign up and onboard HemeScreen™ customers

Precipio continues to sign up and onboard HemeScreen™ customers

Mar 7, 2023, 12:00 PM EST - 2 years ago

Precipio continues to sign up and onboard HemeScreen™ customers

ThermoFisher Salesforce Votes Precipio's HemeScreen® as “Best New Product”

Feb 14, 2023, 11:44 AM EST - 2 years ago

ThermoFisher Salesforce Votes Precipio's HemeScreen® as “Best New Product”